vs
太平洋生物科学（ASMB）与Maase Inc.（MAAS）财务数据对比。点击上方公司名可切换其他公司
太平洋生物科学的季度营收约是Maase Inc.的1.1倍（$10.8M vs $9.9M），太平洋生物科学自由现金流更多（$-15.2M vs $-18.3M）
该公司是一家成立于2004年的美国生物科技企业，主要研发生产基因测序相关设备，同时也开展新型实时生物观测技术相关业务。目前拥有两大核心测序平台，分别是基于零模波导特性的单分子实时测序平台，以及结合天然核苷酸无痕连接技术的结合测序平台。
ASMB vs MAAS — 直观对比
营收规模更大
ASMB
是对方的1.1倍
$9.9M
自由现金流更多
ASMB
多$3.1M
$-18.3M
损益表 — Q3 FY2025 vs Q2 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $10.8M | $9.9M |
| 净利润 | $-9.2M | — |
| 毛利率 | — | 78.7% |
| 营业利润率 | -100.9% | -55.9% |
| 净利率 | -85.2% | — |
| 营收同比 | 57.6% | — |
| 净利润同比 | 4.3% | — |
| 每股收益（稀释后） | $-0.72 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASMBMAAS
| Q3 25 | $10.8M | — | ||
| Q2 25 | $9.6M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $7.4M | — | ||
| Q3 24 | $6.8M | — | ||
| Q2 24 | $8.5M | — | ||
| Q1 24 | $5.8M | — | ||
| Q4 22 | — | $9.9M |
净利润ASMBMAAS
| Q3 25 | $-9.2M | — | ||
| Q2 25 | $-10.2M | — | ||
| Q1 25 | $-8.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-9.6M | — | ||
| Q2 24 | $-11.2M | — | ||
| Q1 24 | $-9.1M | — | ||
| Q4 22 | — | — |
毛利率ASMBMAAS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 22 | — | 78.7% |
营业利润率ASMBMAAS
| Q3 25 | -100.9% | — | ||
| Q2 25 | -115.2% | — | ||
| Q1 25 | -105.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -160.1% | — | ||
| Q2 24 | -143.0% | — | ||
| Q1 24 | -185.5% | — | ||
| Q4 22 | — | -55.9% |
净利率ASMBMAAS
| Q3 25 | -85.2% | — | ||
| Q2 25 | -105.9% | — | ||
| Q1 25 | -93.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -140.4% | — | ||
| Q2 24 | -130.7% | — | ||
| Q1 24 | -156.9% | — | ||
| Q4 22 | — | — |
每股收益（稀释后）ASMBMAAS
| Q3 25 | $-0.72 | — | ||
| Q2 25 | $-1.33 | — | ||
| Q1 25 | $-1.17 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.51 | — | ||
| Q2 24 | $-1.98 | — | ||
| Q1 24 | $-1.66 | — | ||
| Q4 22 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.5M | $10.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $182.7M | $31.6M |
| 总资产 | $240.0M | $47.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASMBMAAS
| Q3 25 | $22.5M | — | ||
| Q2 25 | $24.0M | — | ||
| Q1 25 | $23.4M | — | ||
| Q4 24 | $38.3M | — | ||
| Q3 24 | $28.5M | — | ||
| Q2 24 | $19.2M | — | ||
| Q1 24 | $18.7M | — | ||
| Q4 22 | — | $10.9M |
股东权益ASMBMAAS
| Q3 25 | $182.7M | — | ||
| Q2 25 | $18.1M | — | ||
| Q1 25 | $27.1M | — | ||
| Q4 24 | $33.4M | — | ||
| Q3 24 | $26.0M | — | ||
| Q2 24 | $34.7M | — | ||
| Q1 24 | $32.6M | — | ||
| Q4 22 | — | $31.6M |
总资产ASMBMAAS
| Q3 25 | $240.0M | — | ||
| Q2 25 | $80.8M | — | ||
| Q1 25 | $99.0M | — | ||
| Q4 24 | $119.2M | — | ||
| Q3 24 | $100.3M | — | ||
| Q2 24 | $115.3M | — | ||
| Q1 24 | $119.9M | — | ||
| Q4 22 | — | $47.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.1M | $-18.2M |
| 自由现金流经营现金流 - 资本支出 | $-15.2M | $-18.3M |
| 自由现金流率自由现金流/营收 | -140.7% | -184.4% |
| 资本支出强度资本支出/营收 | 0.4% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASMBMAAS
| Q3 25 | $-15.1M | — | ||
| Q2 25 | $-16.8M | — | ||
| Q1 25 | $-23.4M | — | ||
| Q4 24 | $-51.1M | — | ||
| Q3 24 | $-15.2M | — | ||
| Q2 24 | $-17.1M | — | ||
| Q1 24 | $-18.4M | — | ||
| Q4 22 | — | $-18.2M |
自由现金流ASMBMAAS
| Q3 25 | $-15.2M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-51.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-17.1M | — | ||
| Q1 24 | $-18.4M | — | ||
| Q4 22 | — | $-18.3M |
自由现金流率ASMBMAAS
| Q3 25 | -140.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -695.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -200.6% | — | ||
| Q1 24 | -317.7% | — | ||
| Q4 22 | — | -184.4% |
资本支出强度ASMBMAAS
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.2% | — | ||
| Q4 22 | — | 1.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASMB
暂无分部数据
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
